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Localization of Short-Chain 
Polyphosphate Enhances its Ability 
to Clot Flowing Blood Plasma
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Stephanie A. Smith3, Alexander J. Donovan4, Damien Kudela5, Galen D. Stucky5, Ying Liu4, 
James H. Morrissey3 & Christian J. Kastrup1
Short-chain polyphosphate (polyP) is released from platelets upon platelet activation, but it is not clear 
if it contributes to thrombosis. PolyP has increased propensity to clot blood with increased polymer 
length and when localized onto particles, but it is unknown whether spatial localization of short-chain 
polyP can accelerate clotting of flowing blood. Here, numerical simulations predicted the effect of 
localization of polyP on clotting under flow, and this was tested in vitro using microfluidics. Synthetic 
polyP was more effective at triggering clotting of flowing blood plasma when localized on a surface than 
when solubilized in solution or when localized as nanoparticles, accelerating clotting at 10–200 fold 
lower concentrations, particularly at low to sub-physiological shear rates typical of where thrombosis 
occurs in large veins or valves. Thus, sub-micromolar concentrations of short-chain polyP can accelerate 
clotting of flowing blood plasma under flow at low to sub-physiological shear rates. However, a 
physiological mechanism for the localization of polyP to platelet or vascular surfaces remains unknown.
PolyP is an activator of blood coagulation through its ability to accelerate the activation of coagulation factors XII, 
XI, and V1,2, and by abrogating tissue factor pathway inhibitor (TFPI) function3,4. Long-chain polyP (hundreds 
to thousands of residues long) appears to be a much more potent activator of clotting, via activation of factor XII 
and the contact pathway, than short-chain polyp5–7. Short-chain polyP (60–100 phosphate residues long) is found 
in dense granules of human platelets and granules of mast cells (acidocalcisomes) and released upon their acti-
vation, while long-chain polyP occurs in microbes and some mammalian cells, such as in prostate cancer7–10. A 
characteristic of long-chain polyP is its ability to aggregate into particles, and this spatial localization may possibly 
contribute to its propensity to accelerate clotting11. It is less clear if there is a pathophysiological role for polyP 
released from human cells in thrombosis3. Short-chain endogenous polyP facilitates activation of FXII in vitro, 
albeit at supraphysiological concentrations12. It can also contribute to clotting in vitro under flow when tissue 
factor (TF) is present13. It is well-known that the local concentration of activators can profoundly influence their 
ability to initiate the clotting of blood14. Localization of polyP onto particles also accelerates coagulation under 
stagnant conditions15. Thus, we hypothesized that short-chain polyP may be a more effective activator when spa-
tially localized onto surfaces, capable of accelerating clotting of flowing blood in vitro without participation of TF.
Initiation of blood coagulation is triggered when the local concentration of activators reaches a critical thresh-
old, upon which the proteolytic cascade amplifies the local concentration of active enzymes to form a cross-linked 
fibrin mesh16,17. The spatial localization of activators to surfaces effectively increases their local concentration, 
allowing coagulation to be triggered with less total amount of activator18,19. Several activators have displayed 
this effect of spatial localization in microfluidic models of clotting, including TF, glass, and bacteria that activate 
prothrombin and factor X20. Flow influences coagulation in a variety of ways and enhances the effects of spatial 
localization21. Flow continuously strips clotting factors from catalytic surfaces, preventing activators from achiev-
ing a critical threshold and ultimately preventing clot initiation22,23. To accelerate clotting of flowing blood, greater 
amounts of activator need to be localized in order to achieve a higher local concentration24. In this study, we used 
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numerical simulations and a microfluidic model of thrombosis to investigate whether the ability of localization to 
enhance clotting extends to short-chain polyP in vitro under flow. The shear rates used in this study range from 
low to sub-physiological (i.e. pathological) shear. These low shear rates mimic those typical of where thrombosis 
occurs in large veins and valves, such as in deep vein thrombosis (DVT) or those associated with airplane econ-
omy class syndrome25–30. This microfluidic model of thrombosis enabled clotting of plasma, or lack thereof, to 
be monitored over many hours in the absence of TF. In contrast to coagulation that occurs from acute injury to 
vessels, such as from puncture that exposes large amounts of TF, thrombosis may initiate over longer periods of 
time and can be potentiated by factor XII2,31–35. Our experiments were designed to determine if localization of 
physiologically-relevant concentrations of platelet-length polyP could contribute to coagulation in vitro at low to 
sub-physiological shear, but they do not validate whether or not localization of platelet-length polyP contributes 
to thrombosis in vivo.
Results
Numerical simulations predict the localization of polyP will increase its coagulability at low 
shear rates. To initially examine how localizing polyP onto surfaces affects thrombin generation, we used a 
two-dimensional numerical simulation that considered diffusion, convection, and the rates of 41 reactions of the 
coagulation cascade (Supplementary Tables S1–3). An established kinetic model for the coagulation cascade was 
used with the addition of polyP>1000 in three reactions that were previously characterized in kinetic assays1,4,5,7,20. 
PolyP was either spatially localized onto the surface of a cylindrical channel or dispersed throughout its volume. 
Shear rates were from 1 s−1 to 120 s−1, a range that encompasses sub-physiological shear rates (< ~10 s−1) and 
shear rates in the inferior vena cava, venous valves, and large veins25–27,36. When polyP was localized onto the 
surface of the channel with a shear rate of 1 s−1, the local thrombin burst was 782-fold higher than when an 
equal amount of polyP was dispersed throughout the volume (1.83 × 10−8 M versus 2.34 × 10−11 M) (Fig. 1A). 
The amount of polyP in the simulations was 7.54 × 10−9 mol, which equates to 30 μ M (with respect to phosphate 
monomer) when the total volume of the simulation was considered. The resulting thrombin burst was a conse-
quence of the higher local concentration of polyP, which led to increased positive feedback from the coagulation 
cascade. Simulations showed that differences in thrombin generation persisted over various shear rates, up to 
60 s−1 (Fig. 1B). However, at a set distance, the difference decreased as shear rate increased, because thrombin was 
rapidly transported down-stream.
Surface-immobilized polyP accelerates clotting of flowing blood plasma. To determine if 
SI-polyP was able to accelerate clotting of flowing blood plasma, synthetic polyP400 was immobilized onto the 
Figure 1. Numerical simulations predict localization of polyP accelerates thrombin production at low 
shear rates. Two-dimensional numerical simulations of the human blood coagulation cascade, comparing 
the generation of thrombin by polyP dispersed throughout a cylindrical channel versus polyP immobilized 
on the channel surface. The channel was 20 mm long with a radius of 2 mm. The overall number of polyP 
molecules was the same in all simulations (7.54 × 10−9 moles). (A) Plots show [thrombin], which is the sum of 
concentrations of thrombin and meizothrombin, for a two-dimensional longitudinal cut of the cylinder at 500 s 
into the simulation. (B) The fold difference in the maximum [thrombin] generated in the channel when polyP 
was surface-immobilized (SI-polyP) versus dispersed (D-polyP) at varying shear rates.
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walls of microfluidic channels (Fig. 2A). Half of each chamber was patterned with biotinylated lipids followed by 
an excess of streptavidin (Fig. 2B). Biotinylated-polyP400 was then flowed through the channel, becoming immo-
bilized onto streptavidin. The surface concentration of SI-polyP400 was varied by diluting biotinylated-polyP400 in 
a solution of biotin-PEG before coating the channel. The concentration of polyP was determined by DAPI stain-
ing. Fluorescence intensities from known concentrations of stained D-polyP, which was soluble and dispersed 
throughout the channel, were used to generate a standard curve and used to calculate the surface concentration of 
SI-polyP (Fig. 2C). The surface concentration of SI-polyP was 300 nmol/m2, and could be decreased to 60 nmol/m2 
by diluting with biotin-PEG. To test the ability of patterned polyP to induce clotting, platelet-poor human 
plasma was flowed through the chambers. Based on the simulation data, we tested the lowest shear (1 s−1) as it 
was predicted to have the largest effect on thrombin generation and therefor clotting. A range of shear rates are 
explored in later experiments. The plasma clotted selectively on areas with immobilized polyP400 (300 nmol/m2) 
in 50–70 min at a shear rate of 1 s−1. No clotting was observed over 5 hr in channels without polyP400 (Fig. 2D). All 
polyP concentrations are reported in terms of phosphate monomer.
Measuring clot times simultaneously at various shear rates. A microfluidic system containing six 
regions with varying shear rates was used to measure clot times of flowing blood plasma (Fig. 3A). The range of 
shear rates was 1–110 s−1, which encompasses physiological shear rates which occur in the inferior vena cava, 
venous valves, and large veins; as well as, sub-physiological shear rates (< ~10 s−1) that occur in pathological con-
texts25–28,36. These calculated shear rates were within 3–8% of the values obtained by measuring the flow velocity 
of micro particles by florescence microscopy. Clotting was monitored by visualizing the movement of fluores-
cent tracer beads specifically in the shear chambers, which became immobilized in clotted regions, and by a 
Figure 2. PolyP induces clotting of flowing blood plasma when localized on a surface at sub-physiological 
shear. (A) Schematic of biotinylated synthetic polyP (cyan) patterned onto the surface of half of a microfluidic 
channel, which induces production of thrombin and clotting (blue) of flowing blood plasma (grey). (B) Images 
of fluorescent-labeled agents flowing and patterned along one side of a microfluidic channel. Biotinylated 
lipids (tagged red) self-assembled on the channel wall. Non-biotinylated lipids (not tagged in these images) 
were simultaneously flowed and patterned on the other side of the chamber using laminar flow patterning. 
Then, streptavidin (tagged green) was flowed through and bound to the biotinylated lipids, followed by flowing 
biotinylated polyP labeled with DAPI (cyan), which bound streptavidin. A substrate (blue) for thrombin was 
activated, indicating initiation of clotting, selectively on patterned polyP400 (300 nmol/m2). Scale bar is 250 μ m. 
(C) Quantifying of the amount of SI-polyP by measuring the fluorescence of DAPI bound to it. Channels with 
SI-polyP were compared to channels without polyP and to channels treated with polyP diluted with biotinylated 
PEG. Inset is a standard curve of known concentrations of solubilized D-polyP, which was used to calculate the 
surface concentration of SI-polyP in coated channels. (D) The clotting times of normal human plasma flowing 
through channels coated with polyP400 at a shear rate of 1 s−1. *p = < 0.01 compared to controls without polyP. 
Data indicate mean ± SEM, n = 3.
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fluorogenic peptide substrate, which fluoresced when cleaved by thrombin during clotting (Fig. 3B). To character-
ize and determine the range of clot times of flowing blood plasma in the microfluidic system, coagulation factor 
VIIa (FVIIa) was used, and added to plasma at a range of concentrations (Fig. 3C). FVIIa does not circulate in 
plasma in appreciable amounts physiologically (~1% of total FVII circulates as FVIIa)37, but is administered dur-
ing severe hemorrhage in some cases to aid in hemostasis at doses of 90 to 270 μ g/kg, which roughly corresponds 
to 1 to 4 μ g/mL in plasma38,39. In the device, plasma containing 16 μ g/mL of FVIIa clotted in approximately 
20–40 min, plasma containing 4 μ g/mL of FVIIa clotted in approximately 60 min, and plasma containing 4 ng/mL 
did not clot within 6 hr. Intermediate clotting times occurred with concentrations of 400 ng/mL and 40 ng/mL and 
were dependent on shear rate. Clot formation always occurred from the channel wall, crudely mimicking how 
physiological thrombus formation occurs from the walls of blood vessels and is shear-dependent40.
Short-chain polyP accelerates clot formation faster when surface-localized than when dis-
persed in nanoparticles or in solution. PolyP160 was previously demonstrated to be a weak initi-
ator of the contact pathway, but we examined the hypothesis that spatially localizing polyP160 onto a surface 
(SI-polyP160) would enhance its ability to contribute to clot formation compared to polyP160 dispersed as nan-
oparticles (NP-polyP160) or in solution (D-polyP160, Fig. 4A). With NP-polyP160 (1 μ M, 250 nm diameter, 
Supplementary Fig. S1), clotting occurred in approximately 170 min and 200 min at a shear rate of 1 s−1 and 22 s−1 
respectively. When a similar amount of polyP160 was localized onto the channel surface, clotting occurred signif-
icantly faster than both NP-polyP160 and D-polyP160. Clotting initiated from the parallel channel shear chamber 
walls, or in areas where the channel expanded from high to very low shear, and progressively grew outwards 
(Fig. 4B). Clotting with D-polyP160 (1 μ M) was 4- to 2.8-fold slower than SI-polyP160 and 1.6- to 0-fold slower than 
NP-polyP160 at all shear rates. Overall, clotting occurred fastest with SI-polyP160 than dispersed polyP160 in either 
soluble or NP forms, even with 6–43 fold less SI-polyP160 in the channels.
Platelet-length polyP can accelerate clotting when surface-localized. The concentration of polyP 
is approximately 1.1 mM in platelets, where it is stored in platelet dense granules, and can reach up to 2–7 μ M 
in blood upon platelet activation41,42. To test whether synthetic polyP similar in length to those found in human 
platelets can clot flowing blood at physiological concentrations, polyP70 was tested (Fig. 4C). Soluble polyP70 
(D-polyP70) at 400 nM did not accelerate clotting of flowing blood plasma at the shear rates tested. In contrast, an 
Figure 3. The microfluidic system used to measure clotting over a range of shear rates. (A) Schematic of the 
microfluidic system. Box (dashed lines) indicates the region where shear rates were varied and clot times were 
measured. (B) Fluorescence images showing that clotting was detected by the cessation of flow of tracer beads 
(pink) and by the cleavage of a substrate for thrombin (blue). Scale bar is 250 μ m. (C) Assessing the range of 
clotting times in this flow system by adding various concentrations of FVIIa to the plasma. Data points indicate 
mean ± SEM, n = 3–4. Red circles indicate p = < 0.05 between the data points, and blue circles indicate p = < 0.01 
between the data points.
www.nature.com/scientificreports/
5Scientific RepoRts | 7:42119 | DOI: 10.1038/srep42119
equivalent amount of SI-polyP70 substantially accelerated clotting, to 70 min and 160 min at shear rates of 1 s−1 
and 110 s−1 respectively. The amount of SI-polyP70 used corresponded to a surface concentration of 24 nmol/m2 
and a total concentration of around 400 nM in the volume of the channel. Initiation time of clotting by SI-polyP70 
was dependent on FXII (Supplementary Fig. S2).
SI-polyP70 and D-polyP70 could not be directly compared to self-assembled nanoparticles of polyP70 
(NP-polyP70), because the solubility of polyP70 is greater than longer chain polyP, and NP-polyP70 was not stable. 
Alternatively, we tested a second formulation of polyP nanoparticles, where polyP70 was coated on silica nano-
particles (SNP-polyP70)43. When SNP-polyP70 was added to plasma at varying shear, clotting occurred in approx-
imately 70 min to 160 min at 200 μ g/mL and 80 min to > 360 min at 20 μ g/mL. These masses of SNP-polyP70 
corresponded to concentrations of polyP70 of 6 μ M and 0.6 μ M, respectively, but include both polyP70 and silica. 
Silica is also an activator of factor XII, so an equal comparison between SI-polyP70 and SNP-polyP70 cannot 
be made. Nevertheless, the clotting times of SI-polyP70 (400 nM) were significantly faster than 20 μ g/mL of a 
Figure 4. PolyP accelerates clotting best when spatially localized onto surfaces, compared to soluble 
polyP and nanoparticles of polyP. (A) Clotting times of plasma by polyP160 at varying shear rates, comparing 
three states of polyP160: solubilized, self-assembled nanoparticles, and surface-immobilized. (B) Time-lapse 
images showing SI-polyP160 initiating clotting (detected by non-flowing beads) from the channel wall (dashed 
lines). Scale bar is 250 μ m. (C) Comparing three states of polyP70: solubilized, surface-immobilized onto the 
microfluidic channels, and immobilized onto silica nanoparticles. Clotting tendencies of plasma containing 
silica nanoparticles coated with polyP70 (SNP-polyP70) compared to soluble and surface-immobilized polyP70 
under shear in the microfluidic device. (D) Comparing two states of long-chain polyP: surface immobilized 
polyP400 and nanoparticles of self-assembled polyP>1000. (E) Schematic summarizing the relationship between 
spatial distribution of polyP and the acceleration of clotting in the above experiments. Data points indicate 
mean ± SEM, *p < 0.001, **p < 0.0001, n = 3–4. Statistical analysis represents comparisons between whole 
curves.
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SNP-polyP70, and were nearly identical to 200 μ g/mL of a SNP-polyP70 even though there was a 15-fold lower 
concentration of polyP70.
Clotting by long-chain polyP is also enhanced by surface localization. To understand if the effect 
of surface localization extends to long-chain polyP, we tested a range of concentrations of long-chain polyP either 
surface localized (SI-polyP400) or dispersed as nanoparticles (NP-polyP>1000). PolyP>1000 naturally self-assembles, 
localizing into nanoparticles of 150 ± 30 nm in diameter in solutions containing Ca2+ at low millimolar concen-
trations11. It is a known activator of clotting under static conditions when dispersed throughout plasma3. We 
compared NP-polyP>1000 to SI-polyP400, rather than SI-polyP>1000, because surface patterning of polyP requires 
biotinylation of the polyP chains, and the biotinylation procedure caused degradation of long chain-lengths of 
polyP. When plasma was flowed over SI-polyP400, clotting occurred in approximately 60 min to 100 min at 7 μ M 
and 140 min to 170 min at 1 μ M at the shear rates examined (Fig. 4D). The clot times using NP-polyP>1000 demon-
strated robust shear- and concentration-dependence at 2000, 200, 20, 7 and 1 μ M. NP-PolyP>1000 was most potent 
at 2000 μ M, initiating clotting at 60 min at 1 and 3 s−1, although requiring 285-fold more phosphate to match the 
propensity of SI-polyP400 to clot flowing plasma under the same conditions.
Discussion
Together, these data show that the spatial localization of synthetic polyP onto surfaces affects its ability to activate 
clotting under flow (Fig. 4E). Short-chain polyP polymers (polyP160 and polyP70) greatly accelerated clotting of 
flowing blood plasma at low to sub-physiological shear when surface-localized onto the walls of microfluidic 
chambers compared to when they are dispersed (nanoparticle or soluble forms). Soluble short-chain polyP only 
clotted stagnant blood (near-zero flow) in our experiments, and clotting did not occur within a span of hours even 
at sub-physiological shear rates. Localization of polyP onto the surface of channels showed the greatest activity 
overall. The concentration at which SI-polyP70 accelerated clotting in vitro is well-within the range of amounts of 
polyP released into plasma following platelet activation. Although it is not known if polyP localizes to cell surfaces 
or thrombi, or to the extent polyP contributes to physiological or pathophysiological coagulation, it is impor-
tant to identify scenarios in which polyP could potentially elicit a role. These results propose that if polyP can 
surface-localize it may contribute to clotting at sub-physiological shear following platelet activation, but further 
in vitro and in vivo experiments are necessary to verify that this is a potential mechanism.
Remarkably, comparing SI-polyP70, SI-polyP160, and SI-polyP400, to each other shows that short-chain polyP 
could match the propensity of longer chain polyP to accelerate clotting under flow. SI-polyP70 accelerated clotting 
to a similar extent as SI-polyP160 and SI-polyP400 with a lower concentration of phosphate. Although clotting times 
were similar between them with respect to surface coverage of full-length polymers. This is likely because shorter 
chains have high surface coverage relative to the amount of monomer. Thus, clotting occurred faster with both 
increasing surface concentration of phosphate and increasing surface coverage.
The simulations predicted the trend observed in vitro. Localization creates high local concentrations of polyP, 
and in the numerical simulations this led to larger thrombin bursts due to increased positive feedback from the 
coagulation cascade. The simulations included polyP binding and inhibiting TFPI and accelerating activation of 
factors V and XI, which all occur in plasma. The mechanism is likely contact system mediated as under stagnant 
conditions FXII contributed to initiation of clotting by polyP, but we did not test this further in flow experiments. 
It was recently shown that short-chain polyP could complex with FXII in vitro to allostericly induce its activation 
at high polyP concentrations of 70–130 μ M12. This polyP-induced activation of FXII was enhanced in the pres-
ence of zinc ions, which is known to bind robustly to both FXII and PolyP3,12. Short-chain polyP can also contrib-
ute to clotting independently of FXII when TF is present13. The results here, without TF, indicate that localization 
can further increase the propensity of short-chain polyP to clot blood plasma.
In these microfluidic experiments, shear rate and concentrations of either FVIIa or polyP influenced the clot-
ting times over several hours. The shear rates mimicked the shear rates that are typical in large veins and valves; 
as well as, pathological shear which occurs it the context of thrombosis. The reported clotting times appear very 
long compared to clotting times in most in vitro, stagnant clotting assays, which occur in seconds to minutes. 
However, residence time of plasma in the microfluidic chambers was only ~10 sec, with plasma being continu-
ously transported into and out of the chamber, and thus the rate of clotting cannot be directly compared to stag-
nant clotting assays. Long clot times were possible in this device, compared to most other flow systems, because 
platelet-poor plasma was recalcified on the device and because TF was not included44. The observed clotting 
times were much slower than what is typical in acute hemostasis and at high concentrations of TF, but they were 
within the time-frame that formation and growth of thrombi occurs inside veins and regions of low shear31–33. 
Thrombosis, in contrast to hemostasis, can involve progressive and gradual clot growth, where there is much less 
TF but increased contribution of factors XI and XII2,45. The clotting times measured in this microfluidic system 
are more representative of clotting times that would occur during thrombosis inside intact veins, rather than 
punctured vessels or stagnant clotting assays. In addition, the shear rates used in our microfluidic model include 
the rates which occur in large veins. Though platelets appear to contribute more to arterial thrombi than venous 
thrombi, they also contribute to venous thrombosis46,47. For example, antiplatelet drugs have also been beneficial 
in treating venous thrombosis47–49.
For several concentrations and chain-lengths of polyP, it was not possible to make equivalent comparisons 
between SI-polyP, NP-polyP, SNP-polyP, and D-polyP, because the chain-length and concentration are important 
determinants of whether polyP self-assembles into particles or remains soluble. The solubility of short-chain 
polyP is greater than long-chain polyP, but solubility also depends on the concentration of polyP and Ca2+. For 
example, polyP160 can be formulated to be soluble or to form NP-polyP by varying the concentration of polyP 
and Ca2+ 11. We used concentrations of polyP160 well below its limit of solubility. PolyP160 was first dissolved into 
water and then diluted into plasma. When added to citrated plasma, soluble polyP likely remained dissolved, as 
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plasma has insufficient free divalent cations to facilitate nanoparticle formation11. Once plasma is recalcified, 
polyP likely remains protein-bound even in the presence of low millimolar amounts of ionic calcium, at least 
for the 35 sec that it is present in the microfluidic devices (Supplementary Fig. S3)11,50. In contrast, NP-polyP 
were formed by precipitating polyP160 in 5 mM Ca2+, generating nanoparticles that were stable for over 6 hr, 
as measured by dynamic light scattering. NP-polyP was diluted in the calcium-saline solution that mixed with 
blood plasma inside the microfluidic devices to keep the nanoparticles intact. The stability of NP-polyP in plasma 
is unknown; however, NP-polyP was initially prepared under supersaturated conditions, and the solubility of 
NP-polyP displays hysteretic behavior11. Thus, a large portion of NP-polyP, once formed, likely remained as NPs 
in the microfluidic devices. Although synthetic polyP was used in these experiments, natural polyP is also typi-
cally bound to calcium51.
In summary, this work shows that spatial localization of synthetic polyP, including short-chain polyP, increases 
its propensity to accelerate clotting of blood plasma at low to sub-physiological shear. The observed clotting times 
were much slower than what is typical in hemostasis, but they were within the time-frame that thrombosis occurs 
inside veins, particularly post-operative deep vein thrombi, which form over a period of days32,33,52. The exper-
iments were designed solely to test if surface-localization of short-chain polyP accelerates clot formation under 
flow, at venous and sub-physiological shear rates. An important observation from this was that when localized, 
short-chain polyP could match the ability of long-chain polyP to accelerate clotting. The concentration required 
to accelerate clotting is markedly reduced when polyP is spatially localized onto surfaces, and to a lesser extent, 
into particles, even under flow and without TF. These biophysical insights provide a potential biophysical mech-
anism by which platelet-length polyP could contribute to thrombosis in regions of low shear, but further work 
is required to validate if this mechanism could indeed extend to in vivo scenarios. This effect of localization may 
potentially contribute to clotting at higher shear when TF is present13. Although these in vitro results, in an arti-
ficial flow system, support the notion that platelet-derived polyP could contribute to coagulation in vivo, the flow 
system used here does not include many factors that normally regulate clotting, such as platelets, platelet-derived 
polyP, red blood cells, immune cells, endothelium and other soluble factors. For these reasons, appropriate 
in vivo models are necessary to verify whether platelet-derived polyP and its spatial localization contributes to 
clot formation and thrombosis.
Materials and Methods
Numerical Simulations. Thrombin generation was modeled with the Transport of Diluted Species module 
of Comsol Multiphysics 4.4 by adding diffusion and convection to a previously reported kinetic model20. Changes 
to the model included the addition of three rate equations to describe the activity of polyP: 1) the binding and 
inhibition of TFPI; TFPI + polyP ↔ TFPI-polyP; kon = 4.0 × 105 M−1s−1, koff = 1.0 × 10−2 s−1, 2) the activation of 
factor V; V + Xa + polyP → Va + Xa + polyP; k = 8.0 × 1012 M−2s−1, 3) the activation of factor XI; XI + IIa + polyP 
→ XIa + IIa + polyP; k = 8.8 × 109 M−2s−1 1,4,5,7,20. The diffusion coefficient for all soluble species was 5 × 10−11 m2/s 
and the velocity profile varied with the shear rate, = −γ ( )v r( ) 1z R rR2
2
w , where vz is the velocity in the axial direc-
tion at each radial coordinate r, R is the cylinder radius, and γw is the shear rate at the cylinder wall. The chemical 
species were flowed into a cylindrical geometry of radius 2 mm and length 20 mm. For each shear rate, [thrombin] 
was sampled after the incoming flow had displaced the channel volume 12.5 times. Both the experiments and 
simulations were performed in the same mass-transfer regime (Pe ≫ 1 and Gz > 3000).
Preparing soluble polyP (D-polyP), self-assembled polyP nanoparticles (NP-polyP), 
polyP-coated silica nanoparticles (SNP-polyP), and surface-immobilized polyP (SI-polyP). To 
make D-polyP, polyP was solubilized and diluted first in water and then added to citrated plasma (frozen citrated 
normal control plasma, Affinity Biologicals Inc.) prior to entering the microfluidic device. NP-polyP was gener-
ated as described previously11. Briefly, soluble polyP was added to a calcium solution (10 mM polyP, 5 mM CaCl2, 
8 mM Tris, pH 6.0) followed by vortexing, during which polyP self-assembled into nanoparticles tightly bound to 
Ca2+ cations11. The formation and size of the nanoparticles were verified after adding them to this calcium solu-
tion by observing the scattering intensity and hydrodynamic diameter, as measured by dynamic light scattering 
(Zetasizer Nano ZSP, Malvern Instruments). NP-polyP formulations were added and diluted in calcium-saline 
solution, rather than the citrated-plasma, prior to entering the microfluidic device. The NP-polyP were stable 
for over 6 hr in these solutions. SNP-polyP70 were made by covalently attaching polyP70 onto silica nanoparti-
cles as previously described43. Synthetic PolyP was generated by solubilization from Maddrell salts and biotiny-
lated as previously described7,50. Synthetic polyP has been previously characterized, including its chain length, 
counterions and clotting activity7,11. Long-chain NP-polyP contained a heterogeneous preparation of very long, 
non-biotinylated polyP polymers ranging from around 200 mers to 1300 mers, referred to here as NP-PolyP>1000. 
Some experiments with SI-polyP employed heterogeneous long-chain biotinylated polyP consisting of chains 50 
to 400 units in length, referred to here as biotin-polyP400. Some experiments employed fractionated material of 
narrower sizes (polyP70 and polyP160)7. All polyP concentrations are stated with respect to the concentration of 
phosphate monomer.
Preparing microfluidic devices with SI-polyP. Microfluidic devices were prepared from polydimethyl-
siloxane (PDMS) as previously described53. Channel dimensions are listed as follows (length × width, 125 μ m 
height for all channels): 1.67 mm × 1000 μ m (1 s−1), 3.33 mm × 500 μ m (3 s−1), 5.83 mm × 286 μ m (10 s−1), 
8.33 mm × 200 μ m (22 s−1), 12.50 mm × 133 μ m (55 s−1), 16.67 mm, 100 μ m (110 s−1). The devices were incu-
bated in saline and kept under vacuum overnight to hydrate and remove air from the channels. Devices 
remained soaked in saline throughout the experiment to aid in coating the surfaces with lipids, and to reduce 
convective flow during experiments in the absence of flow. The devices were coated with phosphatidylcho-
line (PC) vesicles to prevent activation of clotting on the PDMS surface. In devices that were not coated with 
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SI-polyP, vesicles were prepared with egg PC (Avanti Polar Lipids, Alabaster, USA) and fluorescent Texas Red 
1,2-Dihexadecanoyl-sn-Glycero-3-Phosphoethanolamine (DHPE) (Invitrogen) in a 99.5:0.5 molar ratio. 
Lipids were extruded through a 100 nm membrane using a Lipex Thermobarrel Extruder (Northern Lipids, 
Burnaby, Canada). The vesicle solution (10 mg/mL in dH2O) were flowed through microfluidic channels at a 
rate of 1 μ l/min for 15 min and rinsed out with saline. The coating of PC on the channels was stable for at least 
10 hours (Supplementary Fig. S4). For devices where polyP was surface-immobilized, the channel was first 
coated with biotinylated lipids (1 μ l/min, 15 min) and rinsed out with saline. To prepare biotinylated vesicles, 
1-oleoyl-2-[12[biotinyl(aminododecanoyl)]-sn-glycero-3-phosphocholine (biotinylated-PC, Avanti Polar Lipids) 
was mixed with Egg PC and Texas Red DHPE in a molar ratio of 5.0:94.5:0.5 and extruded. Next, streptavi-
din (100 μ g/mL) conjugated to Alexa Fluor® 488 (Molecular Probes, Inc.) was flowed through the device (1 μ l/
min, 40 min) and then rinsed with saline to wash away the unbound, excess streptavidin. Finally, a solution of 
biotin-polyP (50 μ g/mL) and biotinylated-polyethylene glycol (biotin-PEG) (either 0 or 99 molar equivalents to 
biotin-polyP) was flowed through the device (1 μ l/min, 40 min), binding to the patterned streptavidin followed by 
a saline rinse, which resulted in SI-polyP being selectively patterned on the walls of the microfluidic device shear 
chambers. Liposomes and saline were flowed into the device through a combination of inlet and outlet channels 
to achieve laminar flow patterning, such that the parallel streams of fluids were at low Reynolds number (≪ 1) 
and maintained sharp boundaries and excluded the possibility of turbulent flow54,55. This patterning allowed 
specific channel walls of the device to be coated, either all channels in the device, the channels in the shear cham-
bers, or one wall of the chambers. To measure the amount of polyP, it was stained by flowing DAPI (40 μ g/mL in 
15 mM Tris acetate, 300 mM NaCl, 30 mM EDTA, and 0.02% NaN3) into the device. Thrombin generation dur-
ing clotting was detected by adding 125 μ g/mL of fluorescent peptide substrate for thrombin (Boc-Val-Pro-Arg-
4-methylcoumaryl-7-amide, Peptide Institute Inc.) into normal plasma.
Flowing plasma and calcium into devices and measuring clotting. Flow rates were controlled using 
a syringe pump (Harvard Apparatus PHD 2000) by withdrawing solutions out of the outlets of the device at a rate 
of 1 μ l/min. Shear rates in different channels were controlled by the width of each channel, while the residence 
time of plasma within the shear chambers were kept constant (~10 sec) by varying their respective lengths. Tubing 
connected to the outlets of the device were charged with 50 μ l of Egg PC vesicles to prevent clotting from initiating 
in the tubing or syringes. A solution of sodium citrate (10 mM in dH2O) was initially pulled into both inlet chan-
nels to wash out the device and further charge the outlet tubing. Normal citrated human plasma (7 mM citrate) 
and calcium-saline solution (40 mM CaCl2 and 90 mM NaCl) were simultaneously pulled into the device and 
mixed at a ratio of 3:1 to recalcify the plasma, yielding a final free calcium concentration of 4–5 mM56. To measure 
clotting times, fluorescent beads (2.5 μ g/mL, Fluoresbrite Plain YG 1.0 Micron Microsphere, Polysciences Inc.), 
and in some experiments 125 μ g/mL fluorescent thrombin substrate, were mixed into the plasma and time-course 
imaging of each channel was performed using an epifluorescence microscope (Leica DMI6000B). The fluorescent 
beads did not influence clotting times (Supplementary Fig. S5). Clotting was determined by the immobilization 
of the fluorescent beads and in some experiments also by the generation of blue fluorescence upon cleavage of 
the thrombin substrate. In experiments where the effect of nanoparticle polyP (NP-polyP) on clotting was tested, 
the activators were mixed with the calcium solution prior to entering the device. For experiments with soluble 
polyP (D-polyP), polyP was added to the plasma instead to prevent nanoparticle formation. For experiments at 
zero shear, normal or congenital FXII-deficient plasma (Geroge King Bio-Medical, Inc.) and calcium were mixed 
together immediately before flowing them into the device and blocking all outlets to create stagnant plasma.
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